Your cholesterol panel can look fine and still miss what matters. Two people with an LDL of 110 can face very different odds of a heart attack. A standard panel won’t catch that gap. Apolipoprotein B, or ApoB, will. Most doctors don’t order it because usually ApoB just agrees with LDL. The value is in the cases where they disagree.
What does ApoB actually measure?
Think of cholesterol as cargo and the particles carrying it as trucks. LDL measures total cargo on the road. ApoB counts the trucks. It’s the trucks that hit artery walls and start damage, and they don’t load evenly. Two people can haul identical total cholesterol in very different numbers of trucks. More trucks means higher risk, even when LDL looks the same. That’s the case for ApoB: one number that counts every cholesterol-carrying particle, tracking risk more tightly than cholesterol itself.1 Allan Sniderman put it plainly in Current Opinion in Lipidology back in 2014: when LDL and ApoB disagree, risk follows ApoB.
How can LDL look fine while ApoB is high?
The mismatch shows up most in a pattern I see constantly: insulin resistance, weight around the middle, high triglycerides, low HDL. Here LDL particles tend to run small and cholesterol-poor, so LDL undercounts circulating particles.2 Your panel looks reassuring. ApoB doesn’t.
Comparison table: when LDL and ApoB disagree
| Pattern | What it usually means | How I’d use it |
|---|---|---|
| LDL low, ApoB low | Fewer atherogenic particles | Reassuring if the rest of your risk is low |
| LDL borderline, ApoB high | More particles than LDL suggests | Treat risk more seriously |
| LDL fine, triglycerides high, HDL low | Insulin-resistant pattern where LDL can undercount particles | ApoB is especially useful |
| LDL high, ApoB high | The standard panel and particle count agree | The decision is usually already clear |
| LDL and ApoB both low after treatment | Treatment is doing what it should | Do not add complexity just to chase another marker |
The evidence is solid. In a Copenhagen cohort of roughly 95,000 people (JACC, 2024), those with high ApoB relative to LDL carried more than double the cardiovascular risk, even at an LDL around 77 mg/dL that most doctors would dismiss.3 Genetic data agree, ranking ApoB at the top of lipid risk factors while LDL looks more like a downstream marker.4 A 2020 UK Biobank analysis in PLoS Medicine, about 400,000 people, found that controlling for ApoB makes LDL’s apparent effect on heart disease fade while ApoB’s holds steady.5 This doesn’t mean LDL is irrelevant. It means LDL usually tracks closely enough with ApoB to guide care, and ApoB earns its keep when they split.
If your A1C or fasting glucose sits at the high end of normal, you’re more likely to carry the insulin-resistant pattern where LDL understates particle number.
When is ApoB worth asking for?
ApoB matters in specific spots. When your LDL is borderline, say in the 90s, and you’re unsure about pushing lower. When you have insulin resistance: weight around the middle, high triglycerides, low HDL, prediabetes, type 2 diabetes. When heart disease runs early in your family. When you’re deciding whether to start or intensify a statin.
Adding ApoB to a lipid panel usually runs $15 to $30 out of pocket. But cheap isn’t the point. The point is that a high ApoB could change how aggressively you treat your risk.
Where ApoB can mislead
ApoB rarely changes which drug you’d take. Same statins, same add-ons when needed. What it changes is whether to treat and how hard, by clarifying risk in people prone to LDL-ApoB discordance. As of 2026, guidelines are shifting: the new ACC/AHA dyslipidemia guideline gives ApoB more weight,6 and European guidelines set numeric ApoB goals. In the US, treatment targets still mostly revolve around LDL.
The mismatch is also less common than the hype suggests. With modern LDL calculations, only about 1 to 2 percent of people already at their LDL goal turn out to have discordantly high ApoB.7 That’s why for most people, the test just confirms what LDL already said. And while genetic data make a strong population case, no single number dictates one person’s outcome. ApoB sits alongside blood pressure, glucose, smoking, and family history.
Ask for ApoB if you’re on the fence about a statin
If your LDL is borderline and you’re on the fence about a statin, or if you have an insulin-resistant pattern (high triglycerides, low HDL, prediabetes or type 2 diabetes, weight around the middle), ask for ApoB with your next lipid panel. Early family heart disease is another good reason to ask. If none of those apply, skip it. For most people, ApoB just echoes LDL. Rough benchmark: under about 90 mg/dL is reasonable for most, under 80 if you’re already high-risk,8 but your doctor sets the target to your situation.
If ApoB aligns with a low LDL and you have no other risk factors, let it rest. It confirmed the good news, and the right move is nothing. If LDL and ApoB don’t match, that mismatch is the most useful finding the test offers. Take it to whoever manages your heart risk.